OAC after apparently successfull AF ablation: when, why, and how?

Size: px
Start display at page:

Download "OAC after apparently successfull AF ablation: when, why, and how?"

Transcription

1 Gulf EP Live Dubai January / 2015 OAC after apparently successfull AF ablation: when, why, and how? Antonio Raviele, MD, FESC, FHRS Past Director Cardiovascular Department, dell Angelo Hospital, Venice-Mestre, Italy

2 Europace 2012; 14:

3 J Cardiovasc Electrophysiol 2012; 23:

4 Recommendations for Anticoagulation Therapy in Patients Undergoing AF Ablation Systemic anticoagulation with warfarin or a direct thrombin or Factor Xa inhibitor is recommended for at least two months following an AF ablation procedure. Discontinuation of systemic anticoagulation therapy post ablation is not recommended in patients who are at high risk of stroke as estimated by currently recommended schemes (CHADS2 or CHA2DS2VASc). Calkins H et al. Europace 2012; 14: Oral anticoagulation should be started after ablation and continued for at least 3 months in all patients. Oral anticoagulation should be continued indefinitely in most patients who are at moderate or high risk of stroke (based on a risk stratification system such as CHADS 2 or CHA 2 DS 2 -VASc). Raviele A et al. J Cardiovasc Electrophysiol 2012; 23:

5 Discontinuation of OAT after ablation These recommendations come from trials essentially performed in patients treated with antiarrhythmic drugs Only limited data are available in the literature regarding the risk of thromboembolism after successful ablation of AF.

6 Anticoagulation in AF How safe is and when to withdraw anticoagulation in post-ablation patients?

7 Main consideration in favour of OAT Atrial fibrillation is not rarely asymptomatic after AF ablation

8 10% Raviele A et al. J Cardiovasc Electrophysiol 2012; 23:

9 Asymptomatic AF / Detection Methods Standard-12 lead ECG 24-h / 7-d Holter monitoring In-hospital telemetry Mobile continuous outpatient telemetry Event recorder / Intermittent TTEM PM - ICD Device memory External & Implantable loop recorder

10 Prevalence of Asymptomatic AF (%) Discovered incidentally / ECG During AAD Therapy / TTEM PM ICD recipients / Device memory Post-AF Ablation / TTEM, 7-d Holter, 0-20

11 Asymptomatic AF The majority of these episodes are of brief duration and the clinical significance and therapeutic implications of short-lasting asymptomatic AF are still uncertain

12 Another consideration in favour of OAT RF catheter ablation of AF is a procedure that causes an extensive damage of atrial myocardium (up to 20%-30%). The resulting areas of scarring might depress left atrial contractility and predispose to atrial thrombi formation, independent of atrial arrhythmia recurrences

13 AF Ablation & LA Function does AF ablation really impair left atrial function?

14 Effect of RF ablation on LA mechanical function Pts # RF technique LA Function LA size Imaging technique Pappone 01 Lemola 04 Lemola 05 Reant 05 Beukema 05 Tops 05 Verma 06 Takahashi 07 Sacher 08 Marsan 08 Schneider 08 Tops CPVA LACA LACA PVI LACA PVI+LL PVAI Stepwise Stepwise PVI+LL PVI PVI TTE/TEE CT CT TTE TTE TTE TTE/CT TTE TTE RT3DE TTE TTE

15 Eur Heart J 2014; Epub before print January 31, 2014

16 72 Centres in 10 European Countries Eur Heart J 2014; Epub before print January 31, 2014

17 Rate of use of pharmacological treatment at discharge and at the 12-month follow-up. 36% of pts with CHA2DS2-Vasc = 1 24% of pts with CHA2DS2-Vasc > 1 Arbelo E et al. Eur Heart J 2014;eurheartj.ehu001

18 OAT discontinuation after AF ablation The correctness of this behaviour seems to be confirmed by the results of several retrospective studies published in the last years

19 Pts Total Pts in SR Off OAC TE RF 1 FU mths TE (%) Off OAC On OAC Major Bl Oral Nademanee NR Themistoclakis 2010 Off OAC NR Saad Hunter NR Guiot Winkle NR Lin NR NR NR NR NR NR Gaita Riley On OAC Total (81) 6579 (64) 2484 (24) (0.7) 35 (0.5) 35 (1.0) 62 (0.6) 4 (0.06) 57 (1.8)

20 J Am Coll Cardiol 2010; 55:

21 Patient population 3355 Study group: 2692 (80%) Control group: 663 (20%) Themistoclakis S et al. J Am Coll Cardiol 2010; 55:

22 Incidence of Embolic and Hemorrhagic Events Mean follow up: and months Study Group Control Group p Patients, n (%) Tromboembolic events, n (%) 2 (0.07) 3 (0.45) 0.06 Hemorrhagic events, n (%) 1 (0.04) 13 (2.0) <0.001 Themistoclakis S et al. J Am Coll Cardiol 2010; 55:

23 Themistoclakis S et al. J Am Coll Cardiol 2010; 55:

24 Considerations These results suggest that the risk-benefit ratio favors suspension of OAT after successful AF ablation even in pts at moderate-high risk of thromboembolism Themistoclakis S et al. J Am Coll Cardiol 2010; 55:

25 Oral anticoagulation therapy after radiofrequency ablation of atrial fibrillation and the risk of thromboembolism and serious bleeding: long- term follow-up in nationwide cohort of Denmark Deniz Karasoy1*, Gunnar Hilmar Gislason1,2, Jim Hansen1, Arne Johannessen1, Lars Køber3, Morten Hvidtfeldt1, Cengiz O zcan1, Christian Torp-Pedersen1,4, and Morten Lock Hansen1 Eur Heart J 2014;eurheartj.ehu421

26 The cumulative incidences of thromboembolism and serious bleeding according to oral anticoagulation therapy (4050 pts, mean follow-up 3,4 years) Annual incidence of thromboembolism Off-OAC = 0.64% On-OAC = 0.56% Annual incidence of serious bleeding Off-OAC = 0.44% On-OAC = 0.99% Karasoy D et al. Eur Heart J 2014;eurheartj.ehu421

27 Conclusions Thromboembolic risk beyond 3 months after RFA was relatively low compared with a matched non-ablated AF cohort. With cautious interpretation due to low number of events, serious bleeding risk associated with OAC seems to outweigh the benefits of thromboembolic risk reduction

28 Gulf EP Live Dubai January / 2015 OAC after apparently successfull AF ablation: when, why, and how? Antonio Raviele, MD, FESC, FHRS Past Director Cardiovascular Department, dell Angelo Hospital, Venice-Mestre, Italy

29 Suggestions for OAT after ablation (1) The decision to discontinue OAT after apparently successful AF ablation should be still based, in the single patient, on the careful evaluation of the risk/benefit balance between prevention of ischemic stroke and avoidance of hemorrhagic complications

30 Suggestions for OAT after ablation (2) However, according to the results of the above mentioned retrospective studies performed till now, it seems that OAT may be safely interrupted in the majority of post-ablation patients, including those at high trombo-embolic risk

31 Suggestions for OAT after ablation (3) However, this conclusion needs to be confirmed by prospective randomized studies with a sufficient number of patients (at least 3000 patients)

32

33

34 Individual predictors associated with thromboembolism and serious bleeding after first-time radiofrequency ablation. Karasoy D et al. Eur Heart J 2014;eurheartj.ehu421

35

Should AF patients (after ablation) have anticoagulation forever? Can we ever stop it?

Should AF patients (after ablation) have anticoagulation forever? Can we ever stop it? The 12 International Dead Sea Symposium - Jerusalem March 3-5 /2014 Should AF patients (after ablation) have anticoagulation forever? Can we ever stop it? Antonio Raviele, MD, FESC, FHRS Past Director

More information

Causal relationship between AF & stroke

Causal relationship between AF & stroke 7 AP-HRS Scientific Session, New Dehli, India - Oct 29 to Nov 1, 2014 Causal relationship between AF & stroke Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation - Venice,

More information

Causal relationship between AF & stroke

Causal relationship between AF & stroke 7 AP-HRS Scientific Session, New Dehli, India - Oct 29 to Nov 1, 2014 Causal relationship between AF & stroke Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation - Venice,

More information

Role of LAA isolation in AF cure

Role of LAA isolation in AF cure MAM 2017, Zurich Role of LAA isolation in AF cure Sakis Themistoclakis, MD Director, Unit of Electrophysiology and Cardiac Pacing Department of Cardiothoracic & Vascular Medicine Ospedale dell Angelo,

More information

Atrial fibrillation and advanced age

Atrial fibrillation and advanced age Atrial fibrillation and advanced age Prof. Fiorenzo Gaita Director of the Cardiology School University of Turin, Italy Prevalence of AF in the general population Prevalence and age distribution in patients

More information

Can Catheter Ablation of AF Reduce the Risk of Stroke? CCCEP 2015 October 31, 2015

Can Catheter Ablation of AF Reduce the Risk of Stroke? CCCEP 2015 October 31, 2015 Can Catheter Ablation of AF Reduce the Risk of Stroke? CCCEP 2015 October 31, 2015 Atul Verma, MD FRCPC FHRS Director, Heart Rhythm Program Southlake Regional Health Centre Newmarket, Ontario, Canada Chair,

More information

Evaluate Risk of Stroke & Bleeding in AF Patients

Evaluate Risk of Stroke & Bleeding in AF Patients XV World Congress of Arrhythmias, Beijing, China - 17-20 September, 2015 Evaluate Risk of Stroke & Bleeding in AF Patients Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation

More information

Post-ablation Management: Drug therapy, Anticoagulation and long-term Monitoring

Post-ablation Management: Drug therapy, Anticoagulation and long-term Monitoring Catheter Ablation of Atrial Fibrillation: State of the Art Post-ablation Management: Drug therapy, Anticoagulation and long-term Monitoring Dipen Shah Service de Cardiologie Hospital Cantonal de Genève

More information

Atrial Fibrillation Ablation: in Whom and How

Atrial Fibrillation Ablation: in Whom and How Update on Consensus Statement on Management of Atrial Fibrillation: EHRA 2012 Atrial Fibrillation Ablation: in Whom and How Update of HRS/EHRA AF/ECAS Ablation Document 2012 Anne M Gillis MD FHRS Professor

More information

Στυλιανός Τζέης MD, PhD, FESC

Στυλιανός Τζέης MD, PhD, FESC Βραχειάς δια ρκειας ριπε ςυπερκοιλιακη ς ταχυαρρυθμιάς στο Holter ρυθμου η στις συσκευε ςδιαχει ρισης του καρδιακου ρυθμου. Θα χορηγη σουμε αντιθρομβωτικη αγωγη ; Στυλιανός Τζέης MD, PhD, FESC Επιμελητής

More information

Defining Sub-Clinical Atrial Fibrillation and its management

Defining Sub-Clinical Atrial Fibrillation and its management Defining Sub-Clinical Atrial Fibrillation and its management Jeff Healey MD, MSc, FRCP, FHRS PHRI Chair in Cardiology Research Population Health Research Institute McMaster University, Canada Sub-Clinical

More information

Can oral anticoagulants be stopped safely after a successful atrial fibrillation ablation?

Can oral anticoagulants be stopped safely after a successful atrial fibrillation ablation? Review Article Can oral anticoagulants be stopped safely after a successful atrial fibrillation ablation? Tze-Fan Chao 1,2, Yenn-Jiang Lin 1,2, Shih-Lin Chang 1,2, Li-Wei Lo 1,2, Yu-Feng Hu 1,2, Fa-Po

More information

Stratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto

Stratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto Fibrillazione atriale: rischio tromboembolico, Venezia - 27/28 Novembre 2015 Stratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto Antonio Raviele, MD, FESC,

More information

Watchman Implantation Case Presentation and Discussion

Watchman Implantation Case Presentation and Discussion Watchman Implantation Case Presentation and Discussion Walid Saliba, MD, FHRS Director Atrial Fibrillation Center Co-Director AF Stroke Prevention Center Cleveland Clinic Indication FDA NonValvular AF

More information

ΚΑΤΑΛΥΣΗ ΚΟΛΠΙΚΗΣ ΜΑΡΜΑΡΥΓΗΣ. ΥΠΕΡ. Michalis Efremidis MD Second Department of Cardiology Evangelismos General Hospital

ΚΑΤΑΛΥΣΗ ΚΟΛΠΙΚΗΣ ΜΑΡΜΑΡΥΓΗΣ. ΥΠΕΡ. Michalis Efremidis MD Second Department of Cardiology Evangelismos General Hospital ΚΑΤΑΛΥΣΗ ΚΟΛΠΙΚΗΣ ΜΑΡΜΑΡΥΓΗΣ. ΥΠΕΡ. Michalis Efremidis MD Second Department of Cardiology Evangelismos General Hospital Rate control versus Rhythm control for Atrial Fibrillation AFFIRM N Engl J Med 2002;347:1825-33

More information

Papel da imagem na estratificac ão de risco e na predic ão do risco tromboemboĺico

Papel da imagem na estratificac ão de risco e na predic ão do risco tromboemboĺico Imagiologia na Fibrilhac ão Auricular Papel da imagem na estratificac ão de risco e na predic ão do risco tromboemboĺico Mª João Andrade Diagnosis and timely detection of atrial fibrillation Echo-machines

More information

Thromboembolism During Sinus Rhythm in Patients with a History of Atrial Fibrillation

Thromboembolism During Sinus Rhythm in Patients with a History of Atrial Fibrillation 48 th Annual New York Cardiovascular Symposium Thromboembolism During Sinus Rhythm in Patients with a History of Atrial Fibrillation Is Left Atrial Appendage Dysfunction Sufficient to Generate Clots? December

More information

Subclinical AF: Implications of device based episodes

Subclinical AF: Implications of device based episodes Subclinical AF: Implications of device based episodes Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC Disclosures: Clinical Trials and Consulting: Medtronic, Boston Scientific

More information

Επιπλοκές κατάλυσης πνευµονικών φλεβών

Επιπλοκές κατάλυσης πνευµονικών φλεβών Επιπλοκές κατάλυσης πνευµονικών φλεβών Παναγιώτης Ιωαννίδης Διευθυντής Τµήµατος Αρρυθµιών & Επεµβατικής Ηλεκτροφυσιολογίας Βιοκλινικής Αθηνών ΣΕΜΙΝΑΡΙΑ ΟΜΑΔΩΝ ΕΡΓΑΣΙΑΣ Ιωάννινα, 27-2-2015 Solving an equation

More information

Management of Atrial Fibrillation. Leon Ptaszek, MD, PhD, FACC, FHRS 25 March 2018

Management of Atrial Fibrillation. Leon Ptaszek, MD, PhD, FACC, FHRS 25 March 2018 Management of Atrial Fibrillation Leon Ptaszek, MD, PhD, FACC, FHRS 25 March 2018 Disclosures Speaker: St. Jude Medical, Biotronik Consultant: St. Jude Medical, World Care Clinical Objectives Recognize

More information

Implantable Cardiac Monitors for Atrial Fibrillation (AF) Detection: Ready for Routine Use?

Implantable Cardiac Monitors for Atrial Fibrillation (AF) Detection: Ready for Routine Use? Implantable Cardiac Monitors for Atrial Fibrillation (AF) Detection: Ready for Routine Use? Helmut Pürerfellner, MD, Assoc. Prof. Saint Elisabeth s Sisters Hospital Academic Teaching Center Linz/Austria

More information

Κατάλυση παροξυσμικής κολπικής μαρμαρυγής Ποια τεχνολογία και σε ποιους ασθενείς; Χάρης Κοσσυβάκης Καρδιολογικό Τμήμα Γ.Ν.Α. «Γ.

Κατάλυση παροξυσμικής κολπικής μαρμαρυγής Ποια τεχνολογία και σε ποιους ασθενείς; Χάρης Κοσσυβάκης Καρδιολογικό Τμήμα Γ.Ν.Α. «Γ. Κατάλυση παροξυσμικής κολπικής μαρμαρυγής Ποια τεχνολογία και σε ποιους ασθενείς; Χάρης Κοσσυβάκης Καρδιολογικό Τμήμα Γ.Ν.Α. «Γ. ΓΕΝΝΗΜΑΤΑΣ» Rhythm control antiarrhythmic drugs vs catheter ablation Summary

More information

Prof. Fiorenzo Gaita

Prof. Fiorenzo Gaita Adavances in Cardiac Arrhythmias and Great Innovations in Cardiology Turin 2014 Can rhythm control strategy reduce the risk of clinical and silent cerebral ischemia? Prof. Fiorenzo Gaita Director of the

More information

Peri-cardioversion and peri-ablation anticoagulation. Giuseppe Patti Campus Bio-Medico University of Rome

Peri-cardioversion and peri-ablation anticoagulation. Giuseppe Patti Campus Bio-Medico University of Rome Peri-cardioversion and peri-ablation anticoagulation Giuseppe Patti Campus Bio-Medico University of Rome What 2016 ESC guidelines recommend Causes of TE events after cardioversion 1 Preexisting LA thrombosis

More information

Spontaneous Atrial Fibrillation and Noacs and Reversal agents

Spontaneous Atrial Fibrillation and Noacs and Reversal agents Spontaneous Atrial Fibrillation and Noacs and Reversal agents Laurent Lewkowiez, MD Regional Service Chief, Hospital Cardiology CPMG Cardiac Electrophysiology Educational Goals relationship between atrial

More information

Ablation Should Not Be Used as Primary Therapy for Treatment of Patients with Atrial Fibrillation

Ablation Should Not Be Used as Primary Therapy for Treatment of Patients with Atrial Fibrillation Ablation Should Not Be Used as Primary Therapy for Treatment of Patients with Atrial Fibrillation 25 October 2008 Update in Electrocardiography and Arrhythmias Zian H. Tseng, M.D., M.A.S. Assistant Professor

More information

Individual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD

Individual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD Individual Therapeutic Selection Of Anti-coagulants And Periprocedural Management Miguel Valderrábano, MD Outline Does the patient need anticoagulation? Review of clinical evidence for each anticoagulant

More information

Dipen Shah Cardiology Service, University Hospitals, Geneva Switzerland

Dipen Shah Cardiology Service, University Hospitals, Geneva Switzerland Dipen Shah Cardiology Service, University Hospitals, Geneva Switzerland Disclosures Research Grants: Biosense Webster, St. Jude, Bard, Endosense, Biotronik Speakers Honoraria: Biosense Webster, Endosense,

More information

Atrial fibrillation: why it's important to make opportunities diagnosis in single chamber ICD patients

Atrial fibrillation: why it's important to make opportunities diagnosis in single chamber ICD patients ADVANCES IN CARDIAC ARRHYTHMIAS and GREAT INNOVATIONS IN CARDIOLOGY Turin October 13-15, 2016 Atrial fibrillation: why it's important to make opportunities diagnosis in single chamber ICD patients Dott.

More information

קוים מנחים לפרפור פרוזדורים - עדכון משה סויסה מרכז רפואי קפלן

קוים מנחים לפרפור פרוזדורים - עדכון משה סויסה מרכז רפואי קפלן קוים מנחים לפרפור פרוזדורים - עדכון משה סויסה מרכז רפואי קפלן INTRODUCTION The prevalence of atrial fibrillation (AF) is approximately 1.5 2% of the general population The arrhythmia is associated: with

More information

Outcomes of AF Ablation

Outcomes of AF Ablation 2017 춘계심혈관통합학술대회 AF Summit: Atrial Fibrillation Apr.21(Fri) 14:40-16:10 Rm.300B 15:00-15:10 Outcomes of AF Ablation Gi-Byoung Nam MD Asan Medical Center, UUCM 2017 Annual Spring Scientific Conference of

More information

Fibrillation Atriale Paroxystique : ablation, résultats, complications

Fibrillation Atriale Paroxystique : ablation, résultats, complications Fibrillation Atriale Paroxystique : ablation, résultats, complications DIU Rythmologie Paris, le 27/01/16 sboveda@clinique-pasteur.com 1 A disease with bad consequences RR de patients en FA comparé avec

More information

Study period Total sample size (% women) 899 (37.7%) Warfarin Aspirin

Study period Total sample size (% women) 899 (37.7%) Warfarin Aspirin Table S2 Sex- specific differences in oral anticoagulant prescription for stroke prevention in AF Total sample size (% women) Anticoagulant(s) studied Gage (2000) 1 Missouri, USA Discharged during 597

More information

Devices to Protect Against Stroke in Atrial Fibrillation

Devices to Protect Against Stroke in Atrial Fibrillation Devices to Protect Against Stroke in Atrial Fibrillation Jonathan C. Hsu, MD, MAS Associate Clinical Professor Division of Cardiology, Section of Cardiac Electrophysiology June 2, 2018 Disclosures Honoraria

More information

A Cryo Anatomical Procedure to Everyone? Saverio Iacopino, FACC, FESC

A Cryo Anatomical Procedure to Everyone? Saverio Iacopino, FACC, FESC A Cryo Anatomical Procedure to Everyone? Saverio Iacopino, FACC, FESC AF Clinical/Referral Challenge Asymptomatic 40% 3 Rx Effective 30% Failed Rx Ablation Atrial fibrillation (AF) is the most common Candidate

More information

Atrial Fibrillation and the NOAC s. John Raymond MS, PA-C, MHP February 10, 2018

Atrial Fibrillation and the NOAC s. John Raymond MS, PA-C, MHP February 10, 2018 Atrial Fibrillation and the NOAC s John Raymond MS, PA-C, MHP February 10, 2018 Pathogenesis EPIDEMIOLOGY Arrhythmia-related hospitalisations in the US Ventricular fibrillation 2% Atrial fibrillation 34%

More information

Does AF Ablation Lower Stroke Risk? Hugh Calkins MD Professor of Medicine Director of Electrophysiology Johns Hopkins Medical Institutions

Does AF Ablation Lower Stroke Risk? Hugh Calkins MD Professor of Medicine Director of Electrophysiology Johns Hopkins Medical Institutions Does AF Ablation Lower Stroke Risk? Hugh Calkins MD Professor of Medicine Director of Electrophysiology Johns Hopkins Medical Institutions Relationships! Consultant: Medtronic, St Jude, Atricure, Boherringer

More information

Diagnosing atrial fibrillation using implantable devices

Diagnosing atrial fibrillation using implantable devices Diagnosing atrial fibrillation using implantable devices Axel Brandes, MD, FESC Associate Professor of Electrophysiology and Cardiac Arrhythmias Dept. of Cardiology, Odense University Hospital, DK HRC

More information

UTILITY OF THE IMPLANTABLE LOOP RECORDER

UTILITY OF THE IMPLANTABLE LOOP RECORDER UTILITY OF THE IMPLANTABLE LOOP RECORDER John Andriulli, DO Associate Professor of Medicine Director, Arrhythmia Device Program Cooper Medical School of Rowan University Contemporary Practices in Cardiology

More information

Combined catheter ablation and left atrial appendage closure as a. treatment of atrial fibrillation

Combined catheter ablation and left atrial appendage closure as a. treatment of atrial fibrillation Combined catheter ablation and left atrial appendage closure as a hybrid procedure for the treatment of atrial fibrillation Giulio Molon, MD FACC, FESC, Fellow ANMCO Card Dept, S.Cuore hospital Negrar

More information

Long Standing Persistent AF ; CPVI is enough for it

Long Standing Persistent AF ; CPVI is enough for it Long Standing Persistent AF ; CPVI is enough for it Kee-Joon Choi, MD University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea Boston AF Symposium 2012 In a patient undergoing AF ablation

More information

심방세동과최신항응고요법 RACE II AFFIRM 항응고치료는왜중요한가? Rhythm control. Rate control. Anticoagulation 남기병 서울아산병원내과. Clinical Impact of Atrial Fibrillation

심방세동과최신항응고요법 RACE II AFFIRM 항응고치료는왜중요한가? Rhythm control. Rate control. Anticoagulation 남기병 서울아산병원내과. Clinical Impact of Atrial Fibrillation 소강당 심방세동과최신항응고요법 남기병 서울아산병원내과 Clinical Impact of Atrial Fibrillation QoL Hospitalization Stroke CHF Mortality 항응고치료는왜중요한가? Rhythm control Rate control Anticoagulation JACC Vol. 38, No. 4, 2001 AFFIRM RACE

More information

L. Fauchier (1), S. Taillandier (1), I. Lagrenade (1), C. Pellegrin (1), L. Gorin (1), A. Bernard (1), B. Rauzy (1), D. Babuty (1), GYL.

L. Fauchier (1), S. Taillandier (1), I. Lagrenade (1), C. Pellegrin (1), L. Gorin (1), A. Bernard (1), B. Rauzy (1), D. Babuty (1), GYL. Prognosis in patients with atrial fibrillation and CHA 2 DS 2 VASc score=0 in a real world community based cohort study: Loire Valley Atrial Fibrillation project L. Fauchier (1), S. Taillandier (1), I.

More information

Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction

Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction Doron Aronson MD, Gregory Telman MD, Fadel BahouthMD, Jonathan Lessick MD, DSc and Rema Bishara MD Department of Cardiology

More information

Stroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University

Stroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University Stroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University Disclosures Research Grants and speaking fees St. Jude

More information

Left Atrial Appendage Closure Devices. Atrial Fibrillation 10/11/2017

Left Atrial Appendage Closure Devices. Atrial Fibrillation 10/11/2017 Left Atrial Appendage Closure Devices Emile Daoud, MD Chief, Cardiac Electrophysiology Wexner Medical Center, The Ohio State University Atrial Fibrillation 1 Adjusted Annual Stroke Risk Using CHA 2 DS

More information

Rebuttal. Jerónimo Farré MD 2010

Rebuttal. Jerónimo Farré MD 2010 Rebuttal 1.We do not know what are the types of AF in which ablation is worthless or most effective 2.Waiting implies to consider the ablation at an older age and when the duration of the history of AF

More information

Identifying Patients for Anticoagulation: While Many Patients Remain Untreated, Who Should NOT be Anticoagulated?

Identifying Patients for Anticoagulation: While Many Patients Remain Untreated, Who Should NOT be Anticoagulated? Identifying Patients for Anticoagulation: While Many Patients Remain Untreated, Who Should NOT be Anticoagulated? Renato D. Lopes, MD MHS PhD Professor of Medicine Division of Cardiology Duke Clinical

More information

Modest Medtronic. Modest Boehringer Ingelheim

Modest Medtronic. Modest Boehringer Ingelheim Adults With AF (millions) Modest Medtronic Modest Boehringer Ingelheim Changing Modalities of Care for Atrial Fibrillation Jill Repoley MSN, CRNP, CCDS, CEPS, FHRS 7 6 5 4 3 2 1 2.08 2.26 2.44 2.66 2.94

More information

Device detected AF and atrial high rate episodes

Device detected AF and atrial high rate episodes Device detected AF and atrial high rate episodes Professor Paulus Kirchhof University of Birmingham Institute of Cardiovascular Sciences SWBH and UHB NHS trusts, Birmingham, UK Department of Cardiovascular

More information

DOACs for Atrial Fibrillation, Why Are So Many AF Patients NOT on Anticoagulation? David Garcia, MD April 2017

DOACs for Atrial Fibrillation, Why Are So Many AF Patients NOT on Anticoagulation? David Garcia, MD April 2017 DOACs for Atrial Fibrillation, Why Are So Many AF Patients NOT on Anticoagulation? David Garcia, MD April 2017 Disclosures for David Garcia Consultancy: Boehringer Ingelheim; Bristol-Meyers Squibb; Daiichi

More information

Management of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many?

Management of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many? Management of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many? Neal S. Kleiman, MD Houston Methodist DeBakey Heart and Vascular Center, Houston, TX Some Things Are Really Clear 2013

More information

Device Diagnostics and Stroke Prevention: State of the Art

Device Diagnostics and Stroke Prevention: State of the Art Device Diagnostics and Stroke Prevention: State of the Art Ass. Prof. Dr. Carsten W. Israel Dept. of Cardiology Evangelical Hospital Bielefeld Germany C.W.Israel@em.uni-frankfurt.de Disclosure of Relationships

More information

Fibrillazione atriale e scompenso: come interrompere il circolo vizioso.

Fibrillazione atriale e scompenso: come interrompere il circolo vizioso. Alessandria, September 23 th 2017 Fibrillazione atriale e scompenso: come interrompere il circolo vizioso. Professor Fiorenzo Gaita Chief of the Cardiovascular Department Città della Salute e della Scienza

More information

2017 Bryan Health Primary Care Conference. Dale Hansen MD Bryan Heart 5/20/17

2017 Bryan Health Primary Care Conference. Dale Hansen MD Bryan Heart 5/20/17 2017 Bryan Health Primary Care Conference Dale Hansen MD Bryan Heart 5/20/17 I have no financial disclosures or conflicts of interest Bridging Anticoagulation Primum Non Nocere 67 y.o. male with mechanical

More information

NEW APPROACHES AND NEW ANTICOAGULANTS FOR ATRIAL FIBRILLATION

NEW APPROACHES AND NEW ANTICOAGULANTS FOR ATRIAL FIBRILLATION NEW APPROACHES AND NEW ANTICOAGULANTS FOR ATRIAL FIBRILLATION MAY 1, 2015 Melissa R. Robinson, MD FACC FHRS CCDS Assistant Professor of Medicine Director of the Complex Arrhythmia Service POINTS TO MAKE

More information

SUPPLEMENTAL MATERIAL

SUPPLEMENTAL MATERIAL SUPPLEMENTAL MATERIAL 1 Supplemental Table 1. ICD codes Diagnoses, surgical procedures, and pharmacotherapy used for defining the study population, comorbidity, and outcomes Study population Atrial fibrillation

More information

Half Moon Bay Treatment of Atrial Fibrillation. Dr. Roger A. Winkle MD. Silicon Valley Cardiology, PAMF, Sutter Health Sequoia Hospital

Half Moon Bay Treatment of Atrial Fibrillation. Dr. Roger A. Winkle MD. Silicon Valley Cardiology, PAMF, Sutter Health Sequoia Hospital Half Moon Bay 2018 Treatment of Atrial Fibrillation Dr. Roger A. Winkle MD Silicon Valley Cardiology, PAMF, Sutter Health Sequoia Hospital Disclosures: Investor Farapulse Things a Primary Care Doctor Should

More information

What the general cardiologist should know about arrhythmia Stroke prevention in AF" Peter Ammann Kantonsspital St. Gallen

What the general cardiologist should know about arrhythmia Stroke prevention in AF Peter Ammann Kantonsspital St. Gallen What the general cardiologist should know about arrhythmia Stroke prevention in AF" Peter Ammann Kantonsspital St. Gallen What the cardiologist should know about arrhythmia and stroke are there real low

More information

Modifiable Up-Stream Risk Factors:

Modifiable Up-Stream Risk Factors: Modifiable Up-Stream Risk Factors: Recent Studies in AF Prevention Behzad Pavri, MD, FACC, FHRS Professor of Medicine Director, CCEP Fellowship Thomas Jefferson University Hospital, Philadelphia, USA Disclosures

More information

Modern aspects in multidisciplinary thromboembolic prophylaxis. AMPLATZER Left Atrial Appendage data update

Modern aspects in multidisciplinary thromboembolic prophylaxis. AMPLATZER Left Atrial Appendage data update Modern aspects in multidisciplinary thromboembolic prophylaxis AMPLATZER Left Atrial Appendage data update Igal Moarof, MD Interventional Cardiology Kantonsspital Aarau Potential conflicts of interest

More information

Θα πρέπει να αναζηηείηαι η παροσζία ζιωπηλής κολπικής μαρμαρσγή ζε αζθενείς με κρσπηογενές εγκεθαλικό επειζόδιο; Ποιά είναι η καλύηερη μέθοδος;

Θα πρέπει να αναζηηείηαι η παροσζία ζιωπηλής κολπικής μαρμαρσγή ζε αζθενείς με κρσπηογενές εγκεθαλικό επειζόδιο; Ποιά είναι η καλύηερη μέθοδος; Θα πρέπει να αναζηηείηαι η παροσζία ζιωπηλής κολπικής μαρμαρσγή ζε αζθενείς με κρσπηογενές εγκεθαλικό επειζόδιο; Ποιά είναι η καλύηερη μέθοδος; Νικόλαος Φραγκάκης Λέκηορας Καρδιολογίας, FESC Ιπποκράηειο

More information

How Should we Select Patients for Catheter Ablation? Douglas Esberg, MD, FHRS

How Should we Select Patients for Catheter Ablation? Douglas Esberg, MD, FHRS How Should we Select Patients for Catheter Ablation? Douglas Esberg, MD, FHRS November 2, 2018 2 3 4 5 Atrial Flutter Typical isthmus dependent flutter Success rate ~95% Complications 1% (mostly groin

More information

Risk Stratification for Stroke Prevention in Patients with Atrial Fibrillation: The emerging role of biomarkers

Risk Stratification for Stroke Prevention in Patients with Atrial Fibrillation: The emerging role of biomarkers Risk Stratification for Stroke Prevention in Patients with Atrial Fibrillation: The emerging role of biomarkers Banff 2013 CP1221547-8 Meta-Analysis of Stroke 5 Randomized Trials Placebo Stroke Rate 4.5%/yr

More information

ΑΣΥΜΠΤΩΜΑΤΙΚΗ ΚΟΛΠΙΚΗ ΜΑΡΜΑΡΥΓΗ

ΑΣΥΜΠΤΩΜΑΤΙΚΗ ΚΟΛΠΙΚΗ ΜΑΡΜΑΡΥΓΗ ΑΣΥΜΠΤΩΜΑΤΙΚΗ ΚΟΛΠΙΚΗ ΜΑΡΜΑΡΥΓΗ ΓΕΩΡΓΙΟΣ ΣΤΑΥΡΟΠΟΥΛΟΣ Β ΚΑΡΔΙΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΠΓΝΘ ΙΠΠΟΚΡΑΤΕΙΟ 9 Ο Βορειοελλα ATRIAL FIBRILATION Atrial fibrillation (AF) is the most common clinically significant heart

More information

Controversies in Atrial Fibrillation and HF

Controversies in Atrial Fibrillation and HF Controversies in Atrial Fibrillation and HF Dr.Yahya Al Hebaishi Cardiac electrophysiology division, PSCC, Riyadh Atrial Fibrillation: Rate or Rhythm? HF and AF: the twin epidemic of cardiovascular disease.

More information

Cryptogenic Stroke: The role of silent Atrial Fibrillation

Cryptogenic Stroke: The role of silent Atrial Fibrillation Cryptogenic Stroke: The role of silent Atrial Fibrillation PD Dr. med. Martin A. Ritter Westfälische Wilhelms-Universität Münster Germany ritterm@uni-muenster.de 1 Turin, 25.10.2014 Agenda 1. What is a

More information

PRIMARY RESULTS OF RF CATHETER ABLATION FOR AF IN VIETNAM HEART INSTITUTE. PHAM QUOC KHANH, MD, PhD. et al Vietnam Heart Institute

PRIMARY RESULTS OF RF CATHETER ABLATION FOR AF IN VIETNAM HEART INSTITUTE. PHAM QUOC KHANH, MD, PhD. et al Vietnam Heart Institute PRIMARY RESULTS OF RF CATHETER ABLATION FOR AF IN VIETNAM HEART INSTITUTE PHAM QUOC KHANH, MD, PhD. et al Vietnam Heart Institute Background - Forms of Atrial Fibrillation - Clinical type of AF: + paroxysmal

More information

In Whom and When Should Atrial Fibrillation Ablation be Considered?

In Whom and When Should Atrial Fibrillation Ablation be Considered? In Whom and When Should Atrial Fibrillation Ablation be Considered? Christian de Chillou, MD, PhD Department of Cardiology University Hospital Nancy, France ESC 2010 Stockholm, August 30. 2010 2 In Whom?

More information

La terapia non anticoagulante nel paziente con FA secondo le Linee Guida F. CONROTTO

La terapia non anticoagulante nel paziente con FA secondo le Linee Guida F. CONROTTO La terapia non anticoagulante nel paziente con FA secondo le Linee Guida F. CONROTTO Rhythm or rate control strategy? N Engl J Med 2002;347:1834 40 Rate Control versus Electrical Cardioversion for Persistent

More information

Fibrillazione atriale : causa diretta marker di rischio di eventi cerebrovascolari non solo embolici?

Fibrillazione atriale : causa diretta marker di rischio di eventi cerebrovascolari non solo embolici? Fibrillazione atriale : causa diretta marker di rischio di eventi cerebrovascolari non solo embolici? Fabrizio Ammirati Dipartimento Medicina UOC Cardiologia Ospedale GB Grassi ASL Roma 3 Sept 2013 Patients

More information

Manuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de

Manuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de When not to exclude the LAA Manuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de Barcelona mcaste@clinic.ub.es @mcastellamd Normal hearts Patient in sinus rhythm Patient in AF (with

More information

Complicanze aritmiche in riabilitazione dopo CCH.

Complicanze aritmiche in riabilitazione dopo CCH. Complicanze aritmiche in riabilitazione dopo CCH www.fisiokinesiterapia.biz Post-Operative Atrial Fibrillation The rate of AF after cardiac surgery in the 1970s was about 10%, and is now consistently at

More information

Catheter Ablation of Atrial Fibrillation Persistent Atrial Fibrillation Catheter Ablation : where are we?

Catheter Ablation of Atrial Fibrillation Persistent Atrial Fibrillation Catheter Ablation : where are we? Catheter Ablation of Atrial Fibrillation Persistent Atrial Fibrillation Catheter Ablation : where are we? F. HIDDEN-LUCET francoise.hidden-lucet@aphp.fr Pitié-Salpétrière APHP FRANCE Disclosure Statement

More information

ESC Stockholm Arrhythmias & pacing

ESC Stockholm Arrhythmias & pacing ESC Stockholm 2010 Take Home Messages for Practitioners Arrhythmias & pacing Prof. Panos E. Vardas Professor of Cardiology Heraklion University Hospital Crete, Greece Disclosures Small teaching fees from

More information

Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute

Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma

More information

Management of ATRIAL FIBRILLATION. in general practice. 22 BPJ Issue 39

Management of ATRIAL FIBRILLATION. in general practice. 22 BPJ Issue 39 Management of ATRIAL FIBRILLATION in general practice 22 BPJ Issue 39 What is atrial fibrillation? Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in primary care. It is often

More information

Asymptomatic Atrial Fibrillation: Detection and Management. 18 December nd Annual Advances in Heart Disease Palace Hotel, San Francisco

Asymptomatic Atrial Fibrillation: Detection and Management. 18 December nd Annual Advances in Heart Disease Palace Hotel, San Francisco Asymptomatic Atrial Fibrillation: Detection and Management 18 December 2015 32 nd Annual Advances in Heart Disease Palace Hotel, San Francisco Zian H. Tseng, M.D., M.A.S. Associate Professor of Medicine

More information

Ruolo della ablazione della fibrillazione atriale nello scompenso cardiaco

Ruolo della ablazione della fibrillazione atriale nello scompenso cardiaco Ruolo della ablazione della fibrillazione atriale nello scompenso cardiaco Matteo Anselmino Division of Cardiology Città della Salute e della Scienza Hospital University of Turin, Italy Disclosure: Honoraria

More information

Conflicts of Interests

Conflicts of Interests Advances in the Management of Atrial Fibrillation State of the Art in 2013 Overview of AF Stroke risk and anticoagulation Rate control Antiarrhythmic Drug Therapy Catheter ablation Conclusion Hugh Calkins

More information

DECLARATION OF CONFLICT OF INTEREST. Consultant Sanofi Biosense Webster Honorarium Boehringer Ingelheim St Jude Medical

DECLARATION OF CONFLICT OF INTEREST. Consultant Sanofi Biosense Webster Honorarium Boehringer Ingelheim St Jude Medical DECLARATION OF CONFLICT OF INTEREST Consultant Sanofi Biosense Webster Honorarium Boehringer Ingelheim St Jude Medical ESC Congress Paris, France August 27-31, 2011 Risk & Complications of AADs for Rhythm

More information

Anticoagulation, atrial fibrillation in elderly patients with chronic kidney disease

Anticoagulation, atrial fibrillation in elderly patients with chronic kidney disease Anticoagulation, atrial fibrillation in elderly patients with chronic kidney disease Zbigniew Heleniak M.D. Ph.D. Department of Nephrology, Transplantology and Internal Medicine Medical University of Gdansk

More information

FA et Apnée du Sommeil

FA et Apnée du Sommeil FA et Apnée du Sommeil La Réunion Octobre 2017 Pascal Defaye CHU Grenoble-Alpes Obstructive Sleep Apnea and AF Incidence of atrial fibrillation (AF), based on presence or absence of OSA. Cumulative frequency

More information

ATRIAL FIBRILLATION 2018: AN UPDATE ON RECENT DEVELOPMENTS IN DIAGNOSIS AND MANAGEMENT PANOS E. VARDAS, MD, PhD

ATRIAL FIBRILLATION 2018: AN UPDATE ON RECENT DEVELOPMENTS IN DIAGNOSIS AND MANAGEMENT PANOS E. VARDAS, MD, PhD ATRIAL FIBRILLATION 2018: AN UPDATE ON RECENT DEVELOPMENTS IN DIAGNOSIS AND MANAGEMENT PANOS E. VARDAS, MD, PhD Author affiliations: Heart Sector, Hygeia Group Hospitals, Athens, Greece Address for correspondence:

More information

Raphael Rosso MD, Yuval Levi Med. Eng., Sami Viskin MD Tel Aviv Sourasky Medical Center

Raphael Rosso MD, Yuval Levi Med. Eng., Sami Viskin MD Tel Aviv Sourasky Medical Center Radiofrequency Ablation of Atrial Fibrillation: Comparison of Success Rate of Circular Ablation vs Point-by-Point Ablation with Contact Force Assessment in Paroxysmal and Persistent Atrial Fibrillation

More information

Atrial Fibrillation New Approaches, Techniques, and Technology

Atrial Fibrillation New Approaches, Techniques, and Technology New Cardiovascular Horizons 2015 May 28, 2015 New Orleans, Louisiana Atrial Fibrillation New Approaches, Techniques, and Technology State of the Art - - 2015 Richard Abben, M D Director, Cardiac Arrhythmia

More information

ESC CONGRESS HIGHLIGHTS ARRHYTHMIAS. M. Bertini (Ferrara, IT) Conflicts of Interest none

ESC CONGRESS HIGHLIGHTS ARRHYTHMIAS. M. Bertini (Ferrara, IT) Conflicts of Interest none ESC CONGRESS HIGHLIGHTS ARRHYTHMIAS M. Bertini (Ferrara, IT) Conflicts of Interest none Data that may change daily practice... Atrial fibrillation OACs in real life - BEYOND program Halvorsen S 2951 OAC

More information

Gianfranco Buja Senior Teacher University of Padova (Italy)

Gianfranco Buja Senior Teacher University of Padova (Italy) Cardiac origin of embolic stroke New oral anticoagulation therapy for stroke prevention in patients with atrial fibrillation undergoing ablation Venice may, 5-7/ 2016 Cortile Antico Teatro Anatomico 1222

More information

Long-Term ECG Monitoring Using an ILR. Evgeny Pokushalov, MD, PhD

Long-Term ECG Monitoring Using an ILR. Evgeny Pokushalov, MD, PhD Long-Term ECG Monitoring Using an ILR Evgeny Pokushalov, MD, PhD Long- Term ECG Monitoring Using an ILR Evgeny Pokushalov, MD, PhD, FESC State Research Ins;tute of Circula;on Pathology, Novosibirsk, Russia

More information

What s new in my specialty?

What s new in my specialty? What s new in my specialty? Jon Melman, MD Heart Rhythm Specialists McKay-Dee Hospital some would say some would say my specialty 1 some would say my specialty First pacemaker 1958 some would say my specialty

More information

ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION

ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION Frederick Schaller, DO, MACOI,FACP Adjunct Clinical Professor Touro University Nevada DISCLOSURES I have no financial relationships

More information

ADC Slides for Presentation 02/10/2017

ADC Slides for Presentation 02/10/2017 ADC 2017 Slides for Presentation ANTI THROMBOTIC THERAPY FOR NON VALVULAR ATRIAL FIBRILLATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE: CURRENT VIEWS Martin A. Alpert, MD Brent M. Parker Professor of Medicine

More information

AF Ablation in 2015 Why, Who, What and How? Steve Wilton ACC Rockies, Banff March 10, 2015

AF Ablation in 2015 Why, Who, What and How? Steve Wilton ACC Rockies, Banff March 10, 2015 AF Ablation in 2015 Why, Who, What and How? Steve Wilton ACC Rockies, Banff March 10, 2015 Disclosures Research grant: St. Jude medical Speaking: Boehringer-Ingelheim Consulting: Arca Biopharma Learning

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION Table S1 Sex- specific differences in rate- control and rhythm- control strategies in observational studies Study region Study period Total sample size Sex- specific results Ozcan (2001) 1 Mayo Clinic,

More information

Weighing the risk of stroke vs the risk of bleeding: Which AF patients should be anticoagulated?

Weighing the risk of stroke vs the risk of bleeding: Which AF patients should be anticoagulated? Weighing the risk of stroke vs the risk of bleeding: Which AF patients should be anticoagulated? Albert L. Waldo, MD, PhD (Hon) The Walter H. Pritchard Professor of Cardiology, Professor of Medicine,and

More information

Storia dell ablazione della fibrillazione atriale: da dove siamo partiti, dove siamo, dove andremo. Prof. Fiorenzo Gaita

Storia dell ablazione della fibrillazione atriale: da dove siamo partiti, dove siamo, dove andremo. Prof. Fiorenzo Gaita Storia dell ablazione della fibrillazione atriale: da dove siamo partiti, dove siamo, dove andremo Prof. Fiorenzo Gaita Knowledge Idea Serendipity Technology (right tools) Serendipity - discovery of a

More information

Progression of atrial fibrillation: can we prevent it? Early catheter ablation will stop progression of atrial fibrillation pro

Progression of atrial fibrillation: can we prevent it? Early catheter ablation will stop progression of atrial fibrillation pro Progression of atrial fibrillation: can we prevent it? Early catheter ablation will stop progression of atrial fibrillation pro Jerónimo Farré MD, Madrid, ES AF: the kingdom of wishful thinking In AF we

More information

The Challenge. Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Anticoagulation/Stroke

The Challenge. Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Anticoagulation/Stroke Anticoagulation/Stroke Warfarin v new oral anticoagulants post PCI Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Gerry Devlin Chairs: Phillip Matsis & Tony Scott Gerry Devlin Honorary Associate

More information

Atrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases?

Atrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases? Atrial Fibrillaiton and Heart Failure: Anticoagulation therapy in all cases? Nicolas Lellouche Fédération de Cardiologie Hôpital Henri Mondor Créteil Disclosure Statement of Financial Interest I currently

More information

Atrial Fibrillation What are the Options in 2016?

Atrial Fibrillation What are the Options in 2016? Atrial Fibrillation What are the Options in 2016? David Spragg, MD, FHRS Johns Hopkins Hospital Cardiovascular Disease Management October, 2016 Disclosures Consulting, Biosense Webster Overview What is

More information